Mitigating time toxicity in lymphoma and multiple myeloma
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related
interactions that can interfere with patient well-being. In this review, we examine several …
interactions that can interfere with patient well-being. In this review, we examine several …
Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study
T Wästerlid, CE Dietrich, A Oksanen, LD Spångberg… - …, 2024 - Wiley Online Library
Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment,
treatment sequencing, number of treatment lines, and its association with survival have not …
treatment sequencing, number of treatment lines, and its association with survival have not …
[HTML][HTML] Treatment selection for patients with relapsed or refractory follicular lymphoma
AZ Skarbnik, K Patel - Frontiers in Oncology, 2023 - frontiersin.org
Follicular lymphoma (FL) is the second most common lymphoma in the United States and is
characterized by a variable clinical course, disease heterogeneity, and a relapse-and …
characterized by a variable clinical course, disease heterogeneity, and a relapse-and …
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario
A Suleman, SJ Aktar, Z Ante, N Liu… - British Journal of …, 2023 - Wiley Online Library
Bendamustine (B) with rituximab (R) has become the preferred regimen for patients with
indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine …
indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine …